IHE News and Press, iShares U.S. Pharmaceutical From 02/10/24

2024-02-10 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-07 01:53:00 ET Summary A sub-$3trn 2023 for M&A, but new year pipeline gives hope. Rising follow-on equity in 2023 signals latent appetite. Unstoppable debt capital markets hit $8.9trn for FY2023. By Lucille Jones, Senior Manager, Deals Intelligence and...

2024-01-31 04:36:00 ET Summary 2023 was characterized by narrow leadership and multiple expansions. While last year’s gains have led to headline valuations appearing stretched, there are many segments of the market that are not as aggressively priced. With the expectati...

2024-01-19 07:03:28 ET Summary Pharmaceuticals underperformed the S&P 500 in 2023 but have been outperforming the broader market in 2024. The PPH fund offers exposure to pharmaceutical stocks and has outperformed its peers in terms of performance and liquidity. The fund is...

2024-01-16 04:50:00 ET Summary Why US banks could be poised for a rebound? Sectors primed for a pivot if the Fed cuts. The outlook for healthcare and real estate. The potential for interest rate cuts this year by the U.S. Federal Reserve is raising the outlook for ...

2024-01-15 12:40:00 ET Summary All decisions around investing, everything we're seeing everyone doing is now colored by the rate situation. Artificial intelligence is a constantly growing and transforming phenomenon. Unlike artificial intelligence, a lot of the most exciting a...

2024-01-14 03:40:00 ET Summary Shanghai Argo Biopharma entered two agreements with Novartis for a total value of $4.2 billion. San Diego’s Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion. GSK plans to acquire Aiolos Bio, a San Francisco-London s...

2024-01-12 11:27:00 ET Summary Horiba is likely undervalued due to it being under followed, and offers a rare combination of a quality business at an attractive price. The company has high market share in specialized devices in various industries, including automotive, process &am...

2024-01-09 12:36:13 ET More on United States 30-Year Bond Yield: BofA’s FMS: Investor sentiment has picked up with higher growth expectations for 2024 Moody's cuts United States credit outlook to negative, reaffirms ratings For further details see: Ten sur...

2024-01-08 12:53:29 ET Summary Large pharma stocks, including Johnson & Johnson, may be experiencing a shift in favor as investors move away from glamour growth stocks as 2024 gets underway. Johnson & Johnson is a leading global healthcare company with a below-market valua...